FDA Decisions: FDA approvals or rejections of Vascepa for new indications significantly impact investor confidence and stock value.

Clinical Trial Results: Positive outcomes from clinical trials relating to Vascepa's efficacy and safety typically boost the stock price.

Sales Performance: Vascepa's sales figures and market share directly reflect revenue generation and influence investor sentiment.

Competition: The presence of competing drugs in the market can erode Vascepa's market share and negatively affect AMRN's stock value.

Regulatory Landscape: Changes in healthcare regulations or policies concerning pharmaceutical pricing can have a considerable impact.

Patent Protection: The strength and duration of Vascepa's patent protection determine its market exclusivity, influencing investor outlook.

Market Sentiment: Overall investor sentiment towards the pharmaceutical industry and biotechnology companies plays a role.

Economic Conditions: Macroeconomic factors, such as interest rates and economic growth, can influence investment decisions and stock prices.

Company News: News releases, press conferences, and corporate updates from Amarin regarding financial performance affect price.

Analyst Ratings: Recommendations and price targets from financial analysts influence investor perception of AMRN's potential.